“No genotoxicity studies with LANTIDRA were conducted.”
✓ VerifiedFDA pharmacology/toxicology review, p. 21Source ↗
Carcinogenicity
Not conducted; literature hepatic tumors in rats with low islet numbers, risk considered low
“Thus, the carcinogenic risk of LANTIDRA in transplanted patients is considered low.”
✓ VerifiedFDA pharmacology/toxicology review, p. 25Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not applicable: cells not genetically modified
“No genotoxicity studies with LANTIDRA were conducted.”
✓ VerifiedFDA pharmacology/toxicology review, p. 21Source ↗
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Not conducted
“No DART studies with LANTIDRA were conducted.”
✓ VerifiedFDA pharmacology/toxicology review, p. 21Source ↗
Safety pharmacology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Genotox: Ames
Not conducted
“No genotoxicity studies with LANTIDRA were conducted.”
✓ VerifiedFDA pharmacology/toxicology review, p. 21Source ↗
Genotox: in vitro mammalian
Not conducted
“No genotoxicity studies with LANTIDRA were conducted.”
✓ VerifiedFDA pharmacology/toxicology review, p. 21Source ↗
Genotox: in vivo
Not conducted
“No genotoxicity studies with LANTIDRA were conducted.”
✓ VerifiedFDA pharmacology/toxicology review, p. 21Source ↗
Carcinogenicity model
Not conducted; literature: low-number intraportal islet grafts in diabetic rats caused liver tumors, high numbers did not; risk judged low
“This combination of islet number, hyperinsulinism, and hyperglycemia resulted in liver tumors. Transplantation of high numbers of islets did not result in hepatic neoplasms.”
✓ VerifiedFDA pharmacology/toxicology review, p. 25Source ↗
Carcinogenicity timing
Not conducted; published rat islet-transplant literature cited instead
“No carcinogenicity/tumorigenicity studies with LANITDRA were conducted. The applicant cited two publications that examined the potential for hepatic carcinogenicity following intraportal transplantation of allogeneic islets in diabetic rats.”
✓ VerifiedFDA pharmacology/toxicology review, p. 21Source ↗
hERG / QT
Not conducted (no safety pharmacology studies)
“No safety pharmacology studies with LANTIDRA were conducted.”
✓ VerifiedFDA pharmacology/toxicology review, p. 14Source ↗